A Study of Platelet Inhibition, Using a 'Point of Care' Platelet Function Test, following Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction [PINPOINT-PPCI].
View/ Open
Volume
10
Pagination
e0144984
DOI
10.1371/journal.pone.0144984
Journal
PLoS One
Issue
Metadata
Show full item recordAbstract
BACKGROUND: Rapid coronary recanalization following ST-elevation myocardial infarction (STEMI) requires effective anti-platelet and anti-thrombotic therapies. This study tested the impact of door to end of procedure ('door-to-end') time and baseline platelet activity on platelet inhibition within 24hours post-STEMI. METHODS AND FINDINGS: 108 patients, treated with prasugrel and procedural bivalirudin, underwent Multiplate® platelet function testing at baseline, 0, 1, 2 and 24hours post-procedure. Major adverse cardiac events (MACE), bleeding and stent thrombosis (ST) were recorded. Baseline ADP activity was high (88.3U [71.8-109.0]), procedural time and consequently bivalirudin infusion duration were short (median door-to-end time 55minutes [40-70] and infusion duration 30minutes [20-42]). Baseline ADP was observed to influence all subsequent measurements of ADP activity, whereas door-to-end time only influenced ADP immediately post-procedure. High residual platelet reactivity (HRPR ADP>46.8U) was observed in 75% of patients immediately post-procedure and persisted in 24% of patients at 2hours. Five patients suffered in-hospital MACE (4.6%). Acute ST occurred in 4 patients, all were <120mins post-procedure and had HRPR. No significant bleeding was observed. In a post-hoc analysis, pre-procedural morphine use was associated with significantly higher ADP activity following intervention. CONCLUSIONS: Baseline platelet function, time to STEMI treatment and opiate use all significantly influence immediate post-procedural platelet activity.
Authors
Johnson, TW; Mumford, AD; Scott, LJ; Mundell, S; Butler, M; Strange, JW; Rogers, CA; Reeves, BC; Baumbach, ACollections
Language
Licence information
Copyright statements
Except where otherwise noted, this item's license is described as Creative Commons Attribution License
Related items
Showing items related by title, author, creator and subject.
-
Novel whole blood assay for phenotyping platelet reactivity in mice identifies ICAM-1 as a mediator of platelet-monocyte interaction
Armstrong, PCJ; Kirkby, NS; Chan, MV; Finsterbusch, M; Hogg, N; Nourshargh, S; Warner, TD (2015-09-03) -
Platelet responses to agonists in a cohort of highly characterised platelet donors are consistent over time
Garner, SF; Furnell, A; Kahan, BC; Jones, CI; Attwood, A; Harrison, P; Kelly, AM; Goodall, AH; Cardigan, R; Ouwehand, WH (2017-01) -
Platelet transfusions reduce fibrinolysis but do not restore platelet function during trauma hemorrhage
Vulliamy, P; Gillespie, S; Gall, LS; Green, L; Brohi, K; Davenport, RA (2017-09)